Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Convertible Debt (2022 - 2025)

Coeptis Therapeutics Holdings (COEP) has 4 years of Convertible Debt data on record, last reported at $100000.0 in Q3 2025.

  • For Q3 2025, Convertible Debt changed N/A year-over-year to $100000.0; the TTM value through Sep 2025 reached $100000.0, changed N/A, while the annual FY2024 figure was $100000.0, 84.0% down from the prior year.
  • Convertible Debt reached $100000.0 in Q3 2025 per COEP's latest filing, down from $218750.0 in the prior quarter.
  • Across five years, Convertible Debt topped out at $625000.0 in Q4 2023 and bottomed at $58100.0 in Q3 2022.
  • Average Convertible Debt over 4 years is $200808.3, with a median of $101500.0 recorded in 2022.
  • The widest YoY moves for Convertible Debt: up 84.0% in 2024, down 84.0% in 2024.
  • A 4-year view of Convertible Debt shows it stood at $58100.0 in 2022, then surged by 975.73% to $625000.0 in 2023, then plummeted by 84.0% to $100000.0 in 2024, then changed by 0.0% to $100000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Convertible Debt were $100000.0 in Q3 2025, $218750.0 in Q1 2025, and $100000.0 in Q4 2024.